A Randomized Phase II Study to Assess the Activity of TroVax (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer.

Trial Profile

A Randomized Phase II Study to Assess the Activity of TroVax (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2013

At a glance

  • Drugs MVA 5T4 (Primary) ; Docetaxel
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jul 2013 Results will be published in Cancer Immunology, Immunotherapy, in 2013, according to an Oxford BioMedica media release reporting highlights.
    • 10 Oct 2012 Verified results data from the 27 enrolled patients will be presented at the first Immunotherapies and Cancer Vaccines Conference in December 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top